je.st
news
Tag: presented
Tom Murdough presented with Lifetime Achievement Economic Development award
2014-11-26 07:26:43| Toys - Topix.net
Resident Tom Murdough was recognized Nov. 20 for the Lifetime Achievement Economic Development award by The City of Hudson Economic Development Department and Hudson Area Chamber of Commerce. Ed Sogan, president of Hudson City Schools Foundation, presented the award to Murdough at the 2014 Annual Award Breakfast at the Jo-Ann Fabric and Craft Store banquet center.
Tags: development
presented
tom
economic
Tony Attard, BCFA director, presented the lifetime achievement award to Margaret Miller
2014-11-18 15:14:23| Furniture - Topix.net
BRADFORD businesswoman Margaret Miller has received a furniture industry lifetime achievement award in recognition of more than 50 years in the sector. Mrs Miller, who is chairman of Knightsbridge Furniture where she began her career in 1959, was honoured by the British Contract Furnishing Association at its annual lunch attended by 500 industry representatives.
Tags: director
presented
award
miller
Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today
2014-11-17 14:30:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. Data are Embargoed by American Heart Association until 10:45 AM CT Today WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data are embargoed by the American Heart Association until the start of the late-breaking clinical trials session at 10:45 a.m. CT today. About Merck Language: English Contact: MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
today
american
primary
Interim Data from Proof-of-Concept Study of Mercks Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting
2014-11-10 00:53:00| Merck.com - Research & Development News
Dateline City: BOSTON Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Mercks Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Joe Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
study
presented
Adveniras Novel F1A12 Protective Coating Presented at NACE Events
2014-11-07 06:00:00| Coatings World Breaking News
Tags: events
presented
protective
coating
Sites : [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] next »